An open clinical study assessing the efficacy and safety of Factor IX Grifols®, a high‐purity Factor IX concentrate, in patients with severe haemophilia B
暂无分享,去创建一个
[1] M. Makris,et al. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.
[2] J. Horrow,et al. If nothing goes wrong, is everything all right? , 1996, Journal of cardiothoracic and vascular anesthesia.
[3] J. Jorquera. Safety procedures of coagulation factors , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.
[4] Grace Chang,et al. Molecular diagnosis of medical viruses. , 2007, Current issues in molecular biology.
[5] V. Blanchette,et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. , 2005, Blood.
[6] J. Paola. Product selection issues in the management of hemophilia B , 2004 .
[7] J. Di Paola. Product selection issues in the management of hemophilia B. , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[8] J. Astermark,et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.
[9] Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.
[10] M. Haase. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. , 2002, Blood.
[11] J. Lusher. Inhibitor Antibodies to Factor VIII and Factor IX: Management , 2000, Seminars in thrombosis and hemostasis.
[12] M. Köhler. Thrombogenicity of prothrombin complex concentrates. , 1999, Thrombosis research.
[13] S. Schulman,et al. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.
[14] E. Thorland,et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.
[15] J. Goudemand,et al. A Cross-over Pharmacokinetic Study of a Double Viral Inactivated Factor IX Concentrate (15 nm Filtration and SD) Compared to a SD Factor IX Concentrate , 1998, Thrombosis and Haemostasis.
[16] I. Warrier,et al. Development of anaphylactic shock in haemophilia B patients with inhibitors. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[17] J. Katz,et al. Factor IX inhibitors and anaphylaxis in hemophilia B. , 1997, Journal of pediatric hematology/oncology.
[18] N. Key,et al. Factor IX inhibitors and anaphylaxis in haemophilia B , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.
[19] I. Scharrer. The need for highly purified products to treat hemophilia B. , 1995, Acta haematologica.
[20] S. Deitcher,et al. High-purity factor IX concentrates for treatment of hemophilia B: relative purity and thrombogenic potential. , 1995, Acta haematologica.
[21] P. Saidi,et al. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. , 1992, Blood.
[22] M. Clarke,et al. Patients undergoing surgery , 1989 .
[23] J A Hanley,et al. If nothing goes wrong, is everything all right? Interpreting zero numerators. , 1983, JAMA.
[24] D. Green,et al. A More Uniform Measurement of Factor VIII Inhibitors , 1975, Thrombosis and Haemostasis.
[25] D. Mittelman,et al. A System for the Separation of the Components of Human Blood: Quantitative Procedures for the Separation of the Protein Components of Human Plasma1a,b,c , 1950 .
[26] Strong Le,et al. Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. , 1946 .